Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2217/fon.15.114 http://scihub22266oqcxt.onion/10.2217/fon.15.114 C4976870!4976870!26274336     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Future+Oncol 2015 ; 11 (17): 2459-70 Nephropedia Template TP {{tp|p=26274336|t=2015. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia |pdf=|usr=}}{{26274336}} gab.com Text L-asparaginase and venous thromboembolism in acute lymphocytic leukemia JO: Future Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26274336 #FOAvip The occurrence of venous thromboembolism (VTE) in acute lymphocytic leukemia patients receiving L-asparaginase therapy may cause significant morbidity, neurological sequela and possibly worse outcomes. The prophylactic use of antithrombin infusion (to keep antithrombin activity >60%) or low molecular weight heparin (LMWH) may reduce the risk of VTE. The decision to continue L-asparaginase therapy after the development of VTE should be based on anticipated benefits, severity of VTE and the ability to continue therapeutic anticoagulation. In patients receiving asparaginase rechallenge, the use of therapeutic LMWH, monitoring of anti-Xa level and antithrombin level are important. Novel oral anticoagulants are not dependent on antithrombin level, hence offer theoretical advantages over LMWH for the prevention and therapy of asparaginase-related VTE. Twit Text FOAVip L-asparaginase and venous thromboembolism in acute lymphocytic leukemia ????Future Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26274336 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26274336 #FOAvip English Wikipedia <ref>{{Cite pmid|26274336}}</ref> L-asparaginase and venous thromboembolism in acute lymphocytic leukemia #MMPMID26274336 Goyal G; Bhatt VR Future Oncol 2015[Sep]; 11 (17): 2459-70 PMID26274336show ga The occurrence of venous thromboembolism (VTE) in acute lymphocytic leukemia patients receiving L-asparaginase therapy may cause significant morbidity, neurological sequela and possibly worse outcomes. The prophylactic use of antithrombin infusion (to keep antithrombin activity >60%) or low molecular weight heparin (LMWH) may reduce the risk of VTE. The decision to continue L-asparaginase therapy after the development of VTE should be based on anticipated benefits, severity of VTE and the ability to continue therapeutic anticoagulation. In patients receiving asparaginase rechallenge, the use of therapeutic LMWH, monitoring of anti-Xa level and antithrombin level are important. Novel oral anticoagulants are not dependent on antithrombin level, hence offer theoretical advantages over LMWH for the prevention and therapy of asparaginase-related VTE. äL-asparaginase and venous thromboembolism in acute lymphocytic leukemi(epmc).pdf DeepDyve Pubget Overpricing